Anixa Biosciences Inc (ANIX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.07+0.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANIX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 399 industry peers
ANIX — litigation filed
Dated 2026-02-09
Regulation FD Disclosure. On February 9, 2026, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that encouraging patient survival data had been observed in its ovarian cancer CAR-T therapy Phase 1 clinical trial and that regulatory approval had been granted enabling dose escalation in the trial beyond the doses set forth in the original trial protocol. The press release is furnished as Exhibit 99.1 hereto Statements that are not historical fact m…
Why it matters: If the health care sector's revenue growth speeds up, it could benefit Anixa. This would help improve its outlook.
Supportive ifHealth care sector revenue growth rises above 10% year over year.
Worry ifHealth care sector revenue growth stays below 9% year over year.
Why it matters: The earnings report will show how Anixa is doing financially and its future.
Watch forAnixa shares its next earnings date and gives updates on revenue and costs.
Also watch forAnixa delays or fails to announce its next earnings date.
Why it matters: Revenue growth trends affect investor confidence and funding for R&D. A drop signals potential issues.
Worry ifRevenue growth reported below the median for the sector.
Less concerning ifRevenue growth remains above the median for the sector.
Why it matters: The earnings report will show if losses are narrowing or worsening. This impacts future funding and growth.
Watch forEarnings report shows a smaller loss than the previous quarter.
Also watch forEarnings report shows a larger loss than the previous quarter.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$227 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $623 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,498 loss on $10,000 · 55.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.